8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 11, 2026·SEC
Material company update
May 7, 2026·SEC
Apyx Medical Corporation(APYX)Earnings, Financials & Key Ratios
APYX•NASDAQ
Price updated Jun 19, 2026
AboutApyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Show more
- Revenue$53M+9.9%
- EBITDA-$6M+68.3%
- Net Income-$11M+52.2%
- EPS (Diluted)-0.27+59.1%
- Gross Margin36.02%-41.0%
- EBITDA Margin-10.96%+71.1%
- Operating Margin-12.2%+68.9%
- Net Margin-21.22%+56.5%
- ROE-76.88%+32.4%
APYX Key Insights
Apyx Medical Corporation (APYX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 13.8%
✗Weaknesses
- ✗High debt to equity ratio of 2.7x
- ✗Negative free cash flow
- ✗Shares diluted 18.6% in last year
- ✗Expensive at 11.7x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when APYX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
APYX Price & Volume
Apyx Medical Corporation (APYX) stock price & volume — 10-year historical chart
Loading chart...
APYX Growth Metrics
Apyx Medical Corporation (APYX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years6%
5 Years13.78%
3 Years5.89%
TTM18.22%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM54.24%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM60.95%
Return on Capital
10 Years-26.07%
5 Years-29.77%
3 Years-25.16%
Last Year-11.8%
APYX Recent Earnings
Apyx Medical Corporation (APYX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.05+54.5%
$0.11
Rev
$12M+18.7%
$11M
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.03+50.0%
$0.06
Rev
$19M+3.4%
$19M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.05+16.7%
$0.06
Rev
$13M-28.9%
$18M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.09+3.6%
$0.09
Rev
$11M-2.8%
$12M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.05vs $0.11+54.5% | $12Mvs $11M+18.7% |
| Q2 2026 | Mar 10, 2026 | $0.03vs $0.06+50.0% | $19Mvs $19M+3.4% |
| Q4 2025 | Nov 6, 2025 | $0.05vs $0.06+16.7% | $13Mvs $18M-28.9% |
| Q3 2025 | Aug 7, 2025 | $0.09vs $0.09+3.6% | $11Mvs $12M-2.8% |
Based on last 12 quarters of dataView full earnings history →
APYX Peer Comparison
Apyx Medical Corporation (APYX) competitors in Aesthetics, dermatology, and wound care — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SSKN | 806.68K | 0.14 | -0.10 | -8.54% | -21.13% | -360.33% | 5.59 | |
 ARAY | 41.39M | 0.35 | -22.45 | 2.68% | -10.76% | -77.48% | 2.17 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 AEYE | 78.83M | 6.31 | -25.24 | 14.52% | -9.05% | -70.95% | 2.75 | |
 INMD | 849.01M | 13.40 | 9.37 | -6.16% | 23.27% | 13.28% | 0.02 | |
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 | |
 SYK | 117.88B | 307.80 | 36.64 | 11.16% | 12.92% | 15.04% | 0.66 |
Compare APYX vs Peers
Apyx Medical Corporation (APYX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
APYX Income Statement
Apyx Medical Corporation (APYX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 38.88M | 16.69M | 28.23M | 27.71M | 48.52M | 44.51M | 52.35M | 48.1M | 52.84M | 55.9M |
Revenue Growth % | 6.16% | -57.09% | 69.21% | -1.86% | 75.08% | -8.26% | 17.61% | -8.11% | 9.86% | 18.22% |
Cost of Goods Sold | 19.12M | 5.89M | 9.14M | 10.21M | 14.92M | 15.38M | 18.59M | 18.74M | 33.81M | 37.86M |
COGS % of Revenue | 49.18% | 35.32% | 32.37% | 36.83% | 30.74% | 34.55% | 35.51% | 38.96% | 63.98% | - |
Gross Profit | 19.76M▲ 0% | 10.79M▼ 45.4% | 19.09M▲ 76.9% | 17.5M▼ 8.3% | 33.6M▲ 92.0% | 29.13M▼ 13.3% | 33.76M▲ 15.9% | 29.36M▼ 13.0% | 19.03M▼ 35.2% | 18.04M▲ 0% |
Gross Margin % | 50.82% | 64.68% | 67.63% | 63.17% | 69.26% | 65.45% | 64.49% | 61.04% | 36.02% | 32.27% |
Gross Profit Growth % | 10.3% | -45.38% | 76.91% | -8.33% | 91.96% | -13.3% | 15.89% | -13.03% | -35.17% | - |
Operating Expenses | 23.5M | 23.65M | 39.96M | 37.59M | 48.05M | 52.69M | 51.02M | 48.2M | 25.48M | 22.35M |
OpEx % of Revenue | 60.44% | 141.75% | 141.54% | 135.64% | 99.04% | 118.38% | 97.46% | 100.21% | 48.22% | - |
Selling, General & Admin | 21.05M | 21.18M | 36.23M | 33.67M | 43.73M | 48.15M | 48.87M | 43.13M | 36.12M | 31.78M |
SG&A % of Revenue | 54.13% | 126.95% | 128.32% | 121.49% | 90.13% | 108.18% | 93.35% | 89.65% | 68.35% | - |
Research & Development | 2.46M | 2.47M | 3.73M | 3.92M | 4.32M | 4.54M | 4.84M | 5.08M | 3.37M | 3.33M |
R&D % of Revenue | 6.31% | 14.8% | 13.21% | 14.15% | 8.91% | 10.21% | 9.25% | 10.56% | 6.38% | - |
Other Operating Expenses | 0 | -203K | 0 | 0 | 0 | 0 | -2.69M | 0 | -14.01M | 0 |
Operating Income | -5.26M▲ 0% | -13.6M▼ 158.3% | -20.87M▼ 53.4% | -20.08M▲ 3.8% | -14.45M▲ 28.1% | -23.56M▼ 63.1% | -17.26M▲ 26.8% | -18.84M▼ 9.2% | -6.45M▲ 65.8% | -4.31M▲ 0% |
Operating Margin % | -13.54% | -81.51% | -73.91% | -72.47% | -29.78% | -52.94% | -32.97% | -39.18% | -12.2% | -7.7% |
Operating Income Growth % | -38.84% | -158.31% | -53.45% | 3.77% | 28.06% | -63.08% | 26.75% | -9.19% | 65.79% | - |
EBITDA | -4.57M | -12.93M | -20.11M | -19.2M | -13.54M | -22.67M | -16.57M | -18.25M | -5.79M | -3.62M |
EBITDA Margin % | -11.75% | -77.5% | -71.24% | -69.27% | -27.92% | -50.94% | -31.65% | -37.93% | -10.96% | -6.47% |
EBITDA Growth % | -49.41% | -183.02% | -55.56% | 4.57% | 29.44% | -67.38% | 26.93% | -10.13% | 68.26% | 75.38% |
D&A (Non-Cash Add-back) | 696K | 669K | 754K | 887K | 903K | 890K | 692K | 599K | 655K | 687K |
EBIT | -13.7M | -14.59M | -19.83M | -19.36M | -14.81M | -22.9M | -18.8M | -17.4M | -6.45M | -3.66M |
Net Interest Income | -136K | 512K | 1.38M | 195K | 1K | 142K | -1.56M | -4.3M | -4.48M | -4.53M |
Interest Income | 0 | 616K | 1.39M | 241K | 11K | 157K | 921K | 1.61M | 1.11M | 1.05M |
Interest Expense | 136K | 104K | 8K | 46K | 10K | 15K | 2.48M | 5.91M | 5.59M | 5.58M |
Other Income/Expense | -8.57M | -1.09M | 1.03M | 674K | -372K | 651K | -4.02M | -4.46M | -4.39M | -4.41M |
Pretax Income | -5.22M▲ 0% | -13.27M▼ 154.3% | -19.84M▼ 49.5% | -19.41M▲ 2.2% | -14.82M▲ 23.6% | -22.91M▼ 54.6% | -21.28M▲ 7.1% | -23.31M▼ 9.5% | -10.84M▲ 53.5% | -8.71M▲ 0% |
Pretax Margin % | -13.42% | -79.53% | -70.25% | -70.04% | -30.55% | -51.47% | -40.65% | -48.45% | -20.5% | -15.58% |
Income Tax | -156K | -3.78M | -130K | -7.5M | 380K | 367K | -2.43M | 252K | 270K | 364K |
Effective Tax Rate % | 2.99% | 28.46% | 0.66% | 38.66% | -2.56% | -1.6% | 11.43% | -1.08% | -2.49% | -4.18% |
Net Income | -5.06M▲ 0% | 64.01M▲ 1364.5% | -19.71M▼ 130.8% | -11.9M▲ 39.6% | -15.17M▼ 27.5% | -23.18M▼ 52.8% | -18.71M▲ 19.3% | -23.46M▼ 25.4% | -11.21M▲ 52.2% | -9.17M▲ 0% |
Net Margin % | -13.02% | 383.61% | -69.79% | -42.93% | -31.27% | -52.09% | -35.75% | -48.78% | -21.22% | -16.4% |
Net Income Growth % | -28.15% | 1364.5% | -130.79% | 39.63% | -27.54% | -52.81% | 19.28% | -25.38% | 52.22% | 54.24% |
Net Income (Continuing) | -13.68M | -10.78M | -19.71M | -11.91M | -15.2M | -23.28M | -18.85M | -23.56M | -11.11M | -9.08M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 138K | 305K | 211K | 221K | 125K | 291K | 256K |
EPS (Diluted) | -0.16▲ 0% | 1.86▲ 1262.5% | -0.58▼ 131.2% | -0.35▲ 39.7% | -0.44▼ 25.7% | -0.67▼ 52.3% | -0.54▲ 19.4% | -0.66▼ 22.2% | -0.27▲ 59.1% | -0.22▲ 0% |
EPS Growth % | -14.29% | 1262.5% | -131.18% | 39.66% | -25.71% | -52.27% | 19.4% | -22.22% | 59.09% | 60.95% |
EPS (Basic) | -0.16 | 1.93 | -0.58 | -0.35 | -0.44 | -0.67 | -0.54 | -0.66 | -0.27 | - |
Diluted Shares Outstanding | 31.43M | 34.37M | 34.07M | 34.21M | 34.33M | 34.52M | 34.62M | 35.54M | 42.16M | 42.16M |
Basic Shares Outstanding | 31.42M | 33.19M | 34.07M | 34.21M | 34.33M | 34.52M | 34.62M | 35.54M | 42.16M | 42.16M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
APYX Balance Sheet
Apyx Medical Corporation (APYX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 22.55M | 89.52M | 76.66M | 66.09M | 60.74M | 42.97M | 70.36M | 56.44M | 58.47M | 54.8M |
Cash & Short-Term Investments | 9.95M | 78.14M | 58.81M | 41.91M | 30.87M | 10.19M | 43.65M | 31.74M | 31.74M | 31.14M |
Cash Only | 9.95M | 16.47M | 58.81M | 41.91M | 30.87M | 10.19M | 43.65M | 31.74M | 31.74M | 31.14M |
Short-Term Investments | 0 | 61.68M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 4.86M | 5.08M | 9.22M | 17.33M | 21.16M | 18.25M | 14.02M | 15.48M | 16.78M | 12.76M |
Days Sales Outstanding | 45.59 | 111.12 | 119.19 | 228.24 | 159.21 | 149.62 | 97.77 | 117.46 | 115.87 | 87.77 |
Inventory | 6.53M | 5.21M | 5.05M | 4.05M | 6.78M | 11.8M | 9.92M | 7.56M | 8.6M | 9.54M |
Days Inventory Outstanding | 124.57 | 322.82 | 201.65 | 144.86 | 165.86 | 279.99 | 194.83 | 147.31 | 92.86 | 85.49 |
Other Current Assets | 3.03M | 130K | 375K | 0 | 0 | 2.74M | 2.76M | 1.66M | 1.35M | 1.37M |
Total Non-Current Assets | 8.44M | 6.09M | 8.01M | 8.02M | 7.98M | 8.8M | 8.88M | 8.4M | 8.37M | 8.23M |
Property, Plant & Equipment | 6.41M | 5.79M | 7.62M | 7.21M | 6.87M | 7.59M | 7.15M | 6.74M | 6.62M | 6.33M |
Fixed Asset Turnover | 6.07x | 2.88x | 3.70x | 3.84x | 7.06x | 5.87x | 7.33x | 7.14x | 7.99x | 8.52x |
Goodwill | 185K | 185K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 1.69M | 6K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | -187K | -150K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 159K | 114K | 391K | 807K | 1.11M | 1.22M | 1.73M | 1.66M | 1.75M | 1.9M |
Total Assets | 30.99M▲ 0% | 95.61M▲ 208.5% | 84.68M▼ 11.4% | 74.11M▼ 12.5% | 68.72M▼ 7.3% | 51.77M▼ 24.7% | 79.24M▲ 53.0% | 64.84M▼ 18.2% | 66.84M▲ 3.1% | 63.02M▲ 0% |
Asset Turnover | 1.25x | 0.17x | 0.33x | 0.37x | 0.71x | 0.86x | 0.66x | 0.74x | 0.79x | 0.91x |
Asset Growth % | -11.74% | 208.54% | -11.44% | -12.48% | -7.27% | -24.66% | 53.05% | -18.17% | 3.08% | -8.7% |
Total Current Liabilities | 5.97M | 7.7M | 12.24M | 9.15M | 13.21M | 11.85M | 12.74M | 10.72M | 11.7M | 9.45M |
Accounts Payable | 1.58M | 1.42M | 2.44M | 1.51M | 2.63M | 2.67M | 2.71M | 2.62M | 3.06M | 2.63M |
Days Payables Outstanding | 30.22 | 88.14 | 97.35 | 54.03 | 64.38 | 63.35 | 53.25 | 50.93 | 33.01 | 28.44 |
Short-Term Debt | 239K | 0 | 140K | 0 | 0 | 0 | 0 | 0 | 428K | 441K |
Deferred Revenue (Current) | 0 | 0 | 7.91M | 0 | 533K | 853K | 488K | 693K | 0 | 3.37M |
Other Current Liabilities | 2.38M | 3.8M | -2.5M | 811K | 2.12M | 0 | 1.54M | 0 | 8.21M | 3.84M |
Current Ratio | 3.77x | 11.62x | 6.26x | 7.22x | 4.60x | 3.63x | 5.52x | 5.26x | 5.00x | 5.80x |
Quick Ratio | 2.68x | 10.95x | 5.85x | 6.78x | 4.09x | 2.63x | 4.74x | 4.56x | 4.26x | 4.79x |
Cash Conversion Cycle | 139.95 | 345.81 | 223.49 | 319.07 | 260.69 | 366.27 | 239.36 | 213.84 | 175.72 | 144.83 |
Total Non-Current Liabilities | 2.98M | 140K | 1.18M | 1.1M | 1.51M | 2.13M | 39.58M | 39.79M | 40.31M | 40.49M |
Long-Term Debt | 2.6M | 140K | 0 | 0 | 0 | 0 | 33.19M | 33.89M | 34.85M | 35.09M |
Capital Lease Obligations | 0 | 0 | 656K | 312K | 18K | 543K | 4.95M | 4.52M | 4.06M | 16.5M |
Deferred Tax Liabilities | 368K | 150K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 20K | 0 | 519K | 166K | 166K | 181K | 198K | 259K | 347K | 339K |
Total Liabilities | 8.96M | 7.84M | 13.42M | 10.25M | 14.71M | 13.98M | 52.32M | 50.51M | 52.01M | 49.94M |
Total Debt | 2.83M | 140K | 1.13M | 676K | 305K | 796K | 38.5M | 38.76M | 39.34M | 39.46M |
Net Debt | -7.12M | -16.33M | -57.68M | -41.24M | -30.57M | -9.4M | -5.15M | 7.02M | 7.6M | 8.32M |
Debt / Equity | 0.13x | 0.00x | 0.02x | 0.01x | 0.01x | 0.02x | 1.43x | 2.70x | 2.65x | 3.02x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -10.90x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -2.30x |
Interest Coverage | -100.75x | -140.26x | -2478.50x | -420.93x | -1481.00x | -1526.40x | -7.59x | -2.95x | -1.15x | -0.66x |
Total Equity | 22.03M▲ 0% | 87.77M▲ 298.4% | 71.26M▼ 18.8% | 63.86M▼ 10.4% | 54.01M▼ 15.4% | 37.79M▼ 30.0% | 26.92M▼ 28.8% | 14.34M▼ 46.8% | 14.83M▲ 3.5% | 13.09M▲ 0% |
Equity Growth % | -15.98% | 298.37% | -18.81% | -10.38% | -15.42% | -30.02% | -28.76% | -46.75% | 3.46% | -69.32% |
Book Value per Share | 0.70 | 2.55 | 2.09 | 1.87 | 1.57 | 1.09 | 0.78 | 0.40 | 0.35 | 0.31 |
Total Shareholders' Equity | 22.03M | 87.77M | 71.26M | 63.72M | 53.7M | 37.58M | 26.7M | 14.21M | 14.54M | 12.83M |
Common Stock | 33K | 34K | 34K | 34K | 34K | 35K | 35K | 38K | 42K | 42K |
Retained Earnings | -28.5M | 35.51M | 14.52M | 2.62M | -12.55M | -35.73M | -54.45M | -77.91M | -89.12M | -91.23M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -6.71M | -6.36M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 138K | 305K | 211K | 221K | 125K | 291K | 256K |
APYX Cash Flow Statement
Apyx Medical Corporation (APYX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -3.7M | -21.01M | -18.48M | -16.07M | -10.45M | -20.28M | -5.25M | -18.05M | -8M | -7.87M |
Operating CF Margin % | -9.53% | -125.92% | -65.43% | -57.98% | -21.54% | -45.56% | -10.03% | -37.52% | -15.14% | - |
Operating CF Growth % | -30.56% | -467.25% | 12.07% | 13.04% | 34.96% | -94.09% | 74.12% | -243.82% | 55.67% | 124.25% |
Net Income | -5.06M | 64.01M | -19.71M | -11.91M | -15.2M | -23.28M | -18.85M | -23.56M | -11.11M | -9.17M |
Depreciation & Amortization | 696K | 669K | 754K | 887K | 903K | 890K | 692K | 599K | 655K | 719K |
Stock-Based Compensation | 871K | 1.52M | 3.58M | 4.21M | 5.09M | 6.7M | 5.11M | 4.01M | 2M | 1.02M |
Deferred Taxes | -196K | -368K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 503K | -68.45M | 215K | 996K | 603K | 628K | 2.25M | 2.15M | 2.04M | 2.83M |
Working Capital Changes | -516K | -18.4M | -3.32M | -10.25M | -1.84M | -5.22M | 5.54M | -1.25M | -1.59M | -3.4M |
Change in Receivables | -303K | -382K | -3.79M | -558K | -4.9M | 1.92M | 3.97M | -2.04M | -1.32M | -1.31M |
Change in Inventory | -870K | -881K | -2.37M | 615K | -2.86M | -5.57M | 1.46M | 2.26M | -1.07M | -1.72M |
Change in Payables | -23K | -224K | 1.05M | -965K | 1.15M | 67K | 25K | -63K | 355K | 275K |
Cash from Investing | -624K | 29.3M | 60.54M | -581K | -723K | -1.01M | 6.73M | -722K | -1.11M | -1.12M |
Capital Expenditures | -624K | -363K | -1.3M | -581K | -723K | -1.01M | -533K | -722K | -1.11M | -1.12M |
CapEx % of Revenue | 1.6% | 2.18% | 4.61% | 2.1% | 1.49% | 2.27% | 1.02% | 1.5% | 2.11% | 2% |
Acquisitions | 0 | 91.09M | 0 | 0 | 195K | 0 | 7.41M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 29.66M | 0 | 0 | -195K | 0 | -147K | 0 | 0 | 0 |
Cash from Financing | -179K | -2.49M | 147K | -73K | 24K | 217K | 32.17M | 6.75M | 9.58M | 9.64M |
Debt Issued (Net) | -239K | -2.69M | -60K | -369K | -238K | -148K | 35.04M | -20K | -20K | -20K |
Equity Issued (Net) | 0 | 0 | 0 | 148K | 67K | 365K | 2.72M | 7M | 9.54M | 9.63M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 60K | 202K | 207K | 148K | 195K | 0 | -5.59M | -235K | 60K | 30K |
Net Change in Cash | -4.51M▲ 0% | 5.8M▲ 228.6% | 42.22M▲ 628.1% | -16.9M▼ 140.0% | -11.04M▲ 34.6% | -20.68M▼ 87.2% | 33.46M▲ 261.8% | -11.91M▼ 135.6% | -1K▲ 100.0% | 126K▲ 0% |
Free Cash Flow | -4.33M▲ 0% | -21.37M▼ 393.9% | -19.78M▲ 7.5% | -16.65M▲ 15.8% | -11.17M▲ 32.9% | -21.29M▼ 90.6% | -5.78M▲ 72.8% | -18.77M▼ 224.6% | -9.12M▲ 51.4% | -8.99M▲ 0% |
FCF Margin % | -11.13% | -128.1% | -70.04% | -60.07% | -23.03% | -47.83% | -11.05% | -39.02% | -17.25% | -16.08% |
FCF Growth % | -38.58% | -393.85% | 7.48% | 15.82% | 32.89% | -90.57% | 72.84% | -224.61% | 51.44% | 31.64% |
FCF per Share | -0.14 | -0.62 | -0.58 | -0.49 | -0.33 | -0.62 | -0.17 | -0.53 | -0.22 | -0.21 |
FCF Conversion (FCF/Net Income) | 0.73x | -0.33x | 0.94x | 1.35x | 0.69x | 0.87x | 0.28x | 0.77x | 0.71x | 0.98x |
Interest Paid | 136K | 104K | 8K | 46K | 10K | 15K | 1.94M | 4.75M | 4.64M | 3.49M |
Taxes Paid | 32K | 13.28M | 325K | 82K | 111K | 128K | 329K | 382K | 258K | 257K |
APYX Key Ratios
Apyx Medical Corporation (APYX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -20.98% | 116.59% | -24.78% | -17.61% | -25.74% | -50.51% | -57.83% | -113.74% | -76.88% | -88.47% |
Return on Invested Capital (ROIC) | -26.54% | -23.62% | -36.82% | -83.22% | -47.05% | -68.18% | -51.6% | -65.54% | -22.08% | -15.9% |
Gross Margin | 50.82% | 64.68% | 67.63% | 63.17% | 69.26% | 65.45% | 64.49% | 61.04% | 36.02% | 32.27% |
Net Margin | -13.02% | 383.61% | -69.79% | -42.93% | -31.27% | -52.09% | -35.75% | -48.78% | -21.22% | -16.4% |
Debt / Equity | 0.13x | 0.00x | 0.02x | 0.01x | 0.01x | 0.02x | 1.43x | 2.70x | 2.65x | 3.02x |
Interest Coverage | -100.75x | -140.26x | -2478.50x | -420.93x | -1481.00x | -1526.40x | -7.59x | -2.95x | -1.15x | -0.66x |
FCF Conversion | 0.73x | -0.33x | 0.94x | 1.35x | 0.69x | 0.87x | 0.28x | 0.77x | 0.71x | 0.98x |
Revenue Growth | 6.16% | -57.09% | 69.21% | -1.86% | 75.08% | -8.26% | 17.61% | -8.11% | 9.86% | 18.22% |
Related:APYX Dividend History·APYX Revenue History·APYX Price History·APYX P/E History·APYX Financial Ratios·APYX Institutional Holders
APYX SEC Filings & Documents
Apyx Medical Corporation (APYX) SEC filings — annual & quarterly reports (10-K, 10-Q)
APYX Frequently Asked Questions
Apyx Medical Corporation (APYX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Apyx Medical Corporation (APYX) reported $55.9M in revenue for fiscal year 2025. This represents a 647% increase from $7.5M in 1996.
Apyx Medical Corporation (APYX) grew revenue by 9.9% over the past year. This is steady growth.
Apyx Medical Corporation (APYX) reported a net loss of $9.2M for fiscal year 2025.
Dividend & Returns
Apyx Medical Corporation (APYX) has a return on equity (ROE) of -76.9%. Negative ROE indicates the company is unprofitable.
Apyx Medical Corporation (APYX) had negative free cash flow of $9.0M in fiscal year 2025, likely due to heavy capital investments.